Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, conferences, and Skype calls has returned with a vengeance. What can you do, though? The world keeps spinning. To cope, we are firing up the coffee kettle and enjoying a hot cup of stimulation. Our choice today is, once again, peppermint mocha, for those tracking this obsession of ours. Meanwhile, here are some tidbits to get you going. Hope you have a smashing day and keep in touch…

As Purdue Pharma grapples with thousands of lawsuits blaming the company for contributing to the opioid crisis, the drug maker has signaled it may file bankruptcy. If that happens, some newly created subsidiaries are likely to come under scrutiny, STAT reports. Over the past year, Purdue launched two limited partnerships now marketing or developing drugs that were previously listed as part of the Purdue product portfolio. Several former Purdue execs run the companies, both of which are referred to as operating subsidiaries, and a Purdue entity holds trademark rights for their names.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy